Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Virology ; 563: 88-97, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34500147

RESUMEN

Two experimental challenge studies were conducted to evaluate the pathogenesis of a porcine parainfluenza virus type 1 (PPIV-1) isolate. Four-week-old conventional (CON) pigs were challenged in Study 1 and six-week-old caesarean derived/colostrum deprived (CDCD) pigs were challenged in Study 2. Results indicate that PPIV-1 shedding and replication occur in the upper and lower respiratory tracts of CON and CDCD pigs as detected by RT-qPCR and immunohistochemistry. Mild macroscopic lung lesions were observed in CON pigs but not in CDCD pigs. Microscopic lung lesions were mild and consisted of peribronchiolar lymphocytic cuffing and epithelial proliferation in CON and CDCD pigs. Serum neutralizing antibodies were detected in the CON and CDCD pigs by 14 and 7 days post inoculation, respectively. This study provides evidence that in spite of PPIV-1 infection and replication in challenged swine, significant clinical respiratory disease was not observed.


Asunto(s)
Cesárea , Calostro/inmunología , Infecciones por Paramyxoviridae/veterinaria , Paramyxoviridae/clasificación , Enfermedades de los Porcinos/virología , Animales , Anticuerpos Neutralizantes , Anticuerpos Antivirales , Enfermedades Pulmonares/veterinaria , Enfermedades Pulmonares/virología , Infecciones por Paramyxoviridae/transmisión , Infecciones por Paramyxoviridae/virología , Porcinos , Enfermedades de los Porcinos/inmunología , Enfermedades de los Porcinos/transmisión , Replicación Viral
2.
Virus Res ; 200: 19-23, 2015 Mar 16.
Artículo en Inglés | MEDLINE | ID: mdl-25645280

RESUMEN

Human metapneumovirus (hMPV) is a major cause of respiratory tract infections in children, elderly and immunocompromised hosts, for which no vaccine or treatment are currently available. Oxidative stress and inflammatory responses represent important pathogenic mechanism(s) of hMPV infection. Here, we explored the potential protective role of dietary antioxidants in hMPV infection. Treatment of airway epithelial cells with resveratrol and quercetin during hMPV infection significantly reduced cellular oxidative damage, inflammatory mediator secretion and viral replication, without affecting viral gene transcription and protein synthesis, indicating that inhibition of viral replication occurred at the level of viral assembly and/or release. Modulation of proinflammatory mediator expression occurred through the inhibition of transcription factor nuclear factor (NF)-κB and interferon regulatory factor (IRF)-3 binding to their cognate site of endogenous gene promoters. Our results indicate the use of dietary antioxidants as an effective treatment approach for modulating hMPV induced lung oxidative damage and inflammation.


Asunto(s)
Antioxidantes/farmacología , Suplementos Dietéticos/análisis , Metapneumovirus/efectos de los fármacos , Infecciones por Paramyxoviridae/virología , Línea Celular , Citocinas/genética , Citocinas/inmunología , Humanos , Metapneumovirus/genética , Metapneumovirus/fisiología , Estrés Oxidativo/efectos de los fármacos , Infecciones por Paramyxoviridae/tratamiento farmacológico , Infecciones por Paramyxoviridae/inmunología , Infecciones por Paramyxoviridae/metabolismo , Quercetina/farmacología , Resveratrol , Estilbenos/farmacología , Replicación Viral/efectos de los fármacos
3.
Avian Pathol ; 38(4): 287-92, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19937513

RESUMEN

Drinking-water treatment with enrofloxacin is widely used to cure respiratory infections in turkeys. The current treatment regimen advises a 5-day treatment at 10 mg/kg body weight. Since enrofloxacin exerts a concentration-dependent activity it might be useful to provide the total treatment dose of 50 mg/kg total dose in a single-day treatment regimen. We therefore assessed whether single-day treatment regimens with 50 mg/kg body weight were clinically equivalent to the advised multiple-day treatment regimen with 10 mg/kg body weight for 5 days. For this purpose, five groups of 16 turkeys, 22 days old, were experimentally inoculated with avian metapneumovirus (APV) and Ornithobacterium rhinotracheale and subsequently treated in the drinking water with enrofloxacin, using either a single-day treatment regimen at 50 mg/kg body weight during a 5-h, 10-h or 20-h period or a standard 5-day treatment regimen at 10 mg/kg body weight/ day for 20 h. Although initially all dosage regimens cleared O. rhinotracheale from the trachea, 4 days after onset of treatment O. rhinotracheale bacteria were re-excreted in the single-day regimens but without worsening of the clinical symptoms. The 5-day treatment with 10 mg enrofloxacin/kg in turkeys provided the best results for the treatment of an O. rhinotracheale infection in turkeys by shortening the course and reducing the severity of clinical disease and by eliminating O. rhinotracheale from the respiratory tract without re-emergence. None of the used treatment regimens promoted the selection of bacterial clones with reduced susceptibility or resistance.


Asunto(s)
Infecciones por Flavobacteriaceae/veterinaria , Fluoroquinolonas/administración & dosificación , Metapneumovirus/patogenicidad , Ornithobacterium , Infecciones por Paramyxoviridae/veterinaria , Enfermedades de las Aves de Corral/terapia , Administración Oral , Animales , Protocolos Clínicos , Farmacorresistencia Bacteriana/efectos de los fármacos , Enrofloxacina , Infecciones por Flavobacteriaceae/terapia , Infecciones por Flavobacteriaceae/virología , Ornithobacterium/patogenicidad , Infecciones por Paramyxoviridae/terapia , Infecciones por Paramyxoviridae/virología , Enfermedades de las Aves de Corral/virología , Tráquea/patología , Resultado del Tratamiento , Pavos
4.
Vet Microbiol ; 121(1-2): 94-104, 2007 Mar 31.
Artículo en Inglés | MEDLINE | ID: mdl-17187945

RESUMEN

Experimental groups of 15 susceptible 3-week-old turkeys were inoculated oculonasally with avian metapneumovirus (APV) subtype A and susceptible Escherichia coli O2:K1 and Ornithobacterium rhinotracheale (ORT) bacteria, with a 3 days interval between viral and bacterial inoculation and approximately 8h between the two bacterial inoculations. The aims of the present study were to assess the efficacy of drinking-water administration of enrofloxacin for 3 and 5 days, amoxicillin for 5 days and florfenicol for 5 days for the treatment of the resulting respiratory disease, based on clinical and bacteriological examinations. Antimicrobial treatment started 1 day after dual bacterial inoculation. After infection, the birds were examined and scored for clinical signs daily, weighed at different times, and their tracheae swabbed daily. Five birds were euthanised and examined for macroscopic lesions at necropsy at 5 days post-bacterial inoculation (dpbi) and the remainder at 15dpbi. Samples of the turbinates, trachea, lungs, sinuses, air sacs, heart, pericardium and liver were collected for bacteriological examination. Recovery from respiratory disease caused by an APV/E. coli/ORT triple infection in 3-week-old turkey poults was overall most successful after enrofloxacin treatment, irrespective of treatment duration, followed by florfenicol treatment. Compared with the untreated group, clinical signs as well as ORT and E. coli multiplication in the respiratory tract were significantly reduced by both enrofloxacin treatments and the florfenicol treatment, with the enrofloxacin treatments showing significantly better reductions than the florfenicol treatment. Five-day treatment with amoxicillin, compared with the untreated group, did not cause a significant reduction in any of the aforementioned parameters.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones por Escherichia coli/veterinaria , Infecciones por Paramyxoviridae/veterinaria , Enfermedades de las Aves de Corral/tratamiento farmacológico , Enfermedades de las Aves de Corral/microbiología , Enfermedades Respiratorias/veterinaria , Pavos , Amoxicilina/uso terapéutico , Animales , Área Bajo la Curva , Peso Corporal/efectos de los fármacos , Enrofloxacina , Escherichia coli/crecimiento & desarrollo , Infecciones por Escherichia coli/complicaciones , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones por Escherichia coli/microbiología , Infecciones por Flavobacteriaceae/complicaciones , Infecciones por Flavobacteriaceae/tratamiento farmacológico , Infecciones por Flavobacteriaceae/microbiología , Infecciones por Flavobacteriaceae/veterinaria , Fluoroquinolonas/uso terapéutico , Metapneumovirus/crecimiento & desarrollo , Pruebas de Sensibilidad Microbiana/veterinaria , Ornithobacterium/crecimiento & desarrollo , Infecciones por Paramyxoviridae/complicaciones , Infecciones por Paramyxoviridae/tratamiento farmacológico , Infecciones por Paramyxoviridae/virología , Enfermedades de las Aves de Corral/virología , Enfermedades Respiratorias/tratamiento farmacológico , Enfermedades Respiratorias/microbiología , Enfermedades Respiratorias/virología , Organismos Libres de Patógenos Específicos , Tianfenicol/análogos & derivados , Tianfenicol/uso terapéutico , Tráquea/microbiología , Tráquea/virología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA